Literature DB >> 25752415

Delayed diagnosis of late-onset Pompe disease in patients with myopathies of unknown origin and/or hyperCKemia.

Jordi Pérez-López1, Albert Selva-O'Callaghan2, Josep M Grau-Junyent3, Luis Gallego-Galindo4, M Josep Coll5, Salvador García-Morillo6, Miguel A Torralba-Cabeza7, Miquel Vilardell-Tarrés8.   

Abstract

Pompe disease is a rare metabolic myopathy whose diagnosis is sometimes delayed despite being essential for improving clinical outcomes. We aimed to investigate the prevalence of late-onset Pompe disease among patients with a myopathy of unknown etiology, including polymyositis, or with idiopathic rise of creatine kinase (CK) levels, in a department of internal medicine. A cohort study was conducted in 241 subjects: 140 patients with myopathies of unknown origin or increased CK levels, 30 with polymyositis and 71 who constituted the control group of other myopathies. Acid α-glucosidase (GAA) activity was tested in dried blood spots. If a positive result was obtained, GAA activity in isolated lymphocytes and/or genetic testing was performed as a confirmatory diagnosis. Out of the 140 investigated patients, 2 patients with myopathies of unknown origin were confirmed to be positive for Pompe disease. Thus, late-onset Pompe disease should be considered among adult patients with myopathy of unknown origin.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alpha glucosidase; Idiopathic hyperCKemia; Maltase deficiency; Myopathy; Pompe disease

Mesh:

Substances:

Year:  2015        PMID: 25752415     DOI: 10.1016/j.ymgme.2015.02.004

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  7 in total

1.  Sensitivity of whole exome sequencing in detecting infantile- and late-onset Pompe disease.

Authors:  Mari Mori; Gloria Haskell; Zoheb Kazi; Xiaolin Zhu; Stephanie M DeArmey; Jennifer L Goldstein; Deeksha Bali; Catherine Rehder; Elizabeth T Cirulli; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2017-10-17       Impact factor: 4.797

2.  Prevalence of Pompe disease in 3,076 patients with hyperCKemia and limb-girdle muscular weakness.

Authors:  Zoltan Lukacs; Paulina Nieves Cobos; Stephan Wenninger; Tracey A Willis; Michela Guglieri; Marc Roberts; Rosaline Quinlivan; David Hilton-Jones; Teresinha Evangelista; Stephan Zierz; Beate Schlotter-Weigel; Maggie C Walter; Peter Reilich; Thomas Klopstock; Marcus Deschauer; Volker Straub; Wolfgang Müller-Felber; Benedikt Schoser
Journal:  Neurology       Date:  2016-05-11       Impact factor: 9.910

3.  A Newborn with Infantile-Onset Pompe Disease Improving after Administration of Enzyme Replacement Therapy: Case Report.

Authors:  Meltem Bor; Ozkan Ilhan; Evren Gumus; Solmaz Ozkan; Meryem Karaca
Journal:  J Pediatr Intensive Care       Date:  2020-07-15

Review 4.  A Multidisciplinary Perspective Addressing the Diagnostic Challenges of Late-Onset Pompe Disease in the Arabian Peninsula Region Developed From an Expert Group Meeting.

Authors:  Ali Al Shehri; Abdullah Al-Asmi; Abdullah Mohammed Al Salti; Abubaker Almadani; Ali Hassan; Ahmed K Bamaga; Edward J Cupler; Jasem Al-Hashel; Majed M Alabdali; Mohammed H Alanazy; Suzan Noori
Journal:  J Neuromuscul Dis       Date:  2022

5.  Pompe disease in Austria: clinical, genetic and epidemiological aspects.

Authors:  W N Löscher; M Huemer; T M Stulnig; P Simschitz; S Iglseder; C Eggers; H Moser; D Möslinger; M Freilinger; F Lagler; S Grinzinger; M Reichhardt; R E Bittner; W M Schmidt; U Lex; M Brunner-Krainz; S Quasthoff; J V Wanschitz
Journal:  J Neurol       Date:  2017-11-27       Impact factor: 4.849

Review 6.  Lysosomes as a therapeutic target.

Authors:  Srinivasa Reddy Bonam; Fengjuan Wang; Sylviane Muller
Journal:  Nat Rev Drug Discov       Date:  2019-09-02       Impact factor: 84.694

7.  High-risk screening of late-onset Pompe disease: A different early portrait in China.

Authors:  Kexin Jiao; Jihong Dong; Sushan Luo; Liqiang Yu; Qing Ke; Zhiqiang Wang; Xinghua Luan; Xiaojie Zhang; Junhong Guo; Yan Chen; Xihua Li; Song Tan; Fangyuan Qian; Jianming Jiang; Xuen Yu; Dongyue Yue; Changxia Liu; Lijun Luo; Jianping Li; Yanzhou Qu; Lan Chen; Jianglong Tu; Chong Sun; Chong Yan; Jie Song; Jianying Xi; Jie Lin; Jiahong Lu; Chongbo Zhao; Wenhua Zhu; Qi Fang
Journal:  Front Neurol       Date:  2022-09-27       Impact factor: 4.086

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.